Ticker

RBGLY, SOUHY and SUNS have been added to the Zacks Rank #5 (Strong Sell) List on April 10, 2026.

Reckitt Benckiser remains a 'Buy' despite near-term macro uncertainty from the Iran War and weak consumer sentiment. RBGLY's core business has been doing fine, with solid growth in emerging markets offsetting lackluster performance in Europe. At a trailing price-to-earnings ratio of 14.5, RBGLY trades at a significant discount to U.S. peers despite strong profitability and reasonable leverage.

Reckitt Benckiser Group PLC (OTCMKTS:RBGLY - Get Free Report)'s share price passed below its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $15.95 and traded as low as $14.11. Reckitt Benckiser Group shares last traded at $14.13, with a volume of 733,330 shares

Reckitt Benckiser Group plc (RBGLY) Presents at UBS Global Consumer and Retail Conference Transcript

UBS maintained its 'buy' rating on Reckitt Benckiser Group PLC (LSE:RKT, FRA:3RB, XETRA:3RB), the consumer goods company behind brands including Dettol, Nurofen and Durex, on Friday but cut its price target by 5% to £74, arguing the market has yet to reward the group for an improved long-term earnings growth model. The note followed Thursday's results, in which Reckitt reported like-for-like (LFL) sales growth of…